Systemic Aspergillosis and Systemic Candidiasis Global Market Report 2024

The systemic aspergillosis and systemic candidiasis market size has grown strongly in recent years. It will grow from $6.82 billion in 2023 to $7.2 billion in 2024 at a compound annual growth rate (CAGR) of 5.5%. The increase observed in the historical period can be attributed to factors such as the rising incidence of fungal infections, a population with compromised immune systems, advancements in diagnostic technologies, an increase in invasive medical procedures, and the global spread of infections.

The systemic aspergillosis and systemic candidiasis market size is expected to see steady growth in the next few years. It will grow to $8.63 billion in 2028 at a compound annual growth rate (CAGR) of 4.6%. The anticipated growth in the forecast period can be linked to efforts in global antifungal resistance surveillance, an aging population, the adoption of telemedicine for remote consultations, a shift toward patient-centric drug development, and the implementation of digital health solutions for patient management. Key trends expected in the forecast period encompass the identification of new fungal biomarkers for early detection, the emergence of novel antifungal agents, advancements in immunotherapy, and the development of innovative drug delivery systems.

The anticipated increase in the incidence of fungal diseases is poised to drive the systemic aspergillosis and systemic candidiasis market's growth. Fungal diseases encompass infections caused by fungi, affecting various body parts and leading to diverse symptoms and complications. These infections range from cutaneous skin issues to respiratory and systemic infections. Antifungal medications, including oral azoles, voriconazole, and liposomal amphotericin B, are commonly employed in treating fungal diseases. For instance, as of March 2023, the Centers for Disease Control and Prevention reported a rise in clinical cases of Candida auris, an emerging fungus, from 476 cases in 2019 to 1,471 cases in 2021 in the United States. Screening cases also tripled from 2020 to 2021, reaching 4,041 cases. Consequently, the increasing incidence of fungal diseases is a key driver of the systemic aspergillosis and systemic candidiasis market.

The upward trajectory in healthcare expenditures is expected to contribute to the systemic aspergillosis and systemic candidiasis market's growth. Healthcare expenditures represent the total spending on medical services, treatments, and health-related expenses within a specified period. Elevated healthcare expenditures play a crucial role in managing systemic aspergillosis and systemic candidiasis by ensuring timely access to antifungal medications, advanced diagnostic tools, and specialized care, thereby improving patient outcomes and reducing mortality rates. Notably, as of December 2022, the Centers for Medicare & Medicaid Services reported a 2.7% increase in healthcare spending in the United States, reaching $12,914 per person in 2021, totaling $4.3 trillion. Healthcare spending accounted for 18.3% of the nation's GDP. Therefore, the surge in healthcare expenditures is a significant driver of the systemic aspergillosis and systemic candidiasis market.

A noteworthy trend in the systemic aspergillosis and systemic candidiasis markets is the emphasis on product innovation by major companies to maintain their market positions. For instance, in October 2021, Intas Pharmaceuticals Limited, an India-based pharmaceutical formulation development, manufacturing, and marketing company, introduced the world's first Super Bioavailable Itraconazole-SB 100mg under the brand name Itaspor-SB Forte/Subawin. This innovative product, designed to enhance patient compliance, allows for reduced dosing and can be consumed with or without food, simply with water. Such product innovations play a vital role in meeting the evolving needs of patients and healthcare professionals.

Major companies in the systemic aspergillosis and systemic candidiasis market are also focusing on advanced solutions, such as next-generation anti-fungal drug agents, to address the growing demand for more effective and targeted treatments. Next-generation anti-fungal drug agents involve advanced medications designed to combat fungal infections more effectively, often incorporating innovative mechanisms or formulations to enhance efficacy and reduce resistance. For example, in October 2023, BDR Pharmaceutical, a US-based pharmaceutical company, launched Zisavel capsules for treating invasive aspergillosis and mucormycosis. This product, belonging to the isavuconazoles class of medications, plays a crucial role in treating invasive aspergillosis and offers a first-line treatment for the specified fungal infections.

In April 2021, Pfizer Inc., a US-based research-based biopharmaceutical company, successfully acquired Amplyx Pharmaceuticals Inc. for an undisclosed amount. This strategic acquisition enables Pfizer to take ownership of Amplyx's early-stage pipeline, featuring potential antiviral (MAU868) and antifungal (APX2039) drugs. Amplyx Pharmaceuticals Inc. is a US-based developer specializing in antifungal agents.

Major companies operating in the systemic aspergillosis and systemic candidiasis market report are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Abbott Laboratories, Sanofi S.A., GlaxoSmithKline PLC, Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Matinas BioPharma Holdings Inc., Shionogi & Co. Ltd., Cipla Limited, Taj Pharmaceuticals Limited, Basilea Pharmaceutica Ltd., Cidara Therapeutics Inc., T2 Biosystems Inc., Sandoz International GmbH, Grupo Ferrer International S.A., Entasis Therapeutics Inc., NovaDigm Therapeutics Inc., F2G Ltd., Mycovia Pharmaceuticals Inc., ContraFect Corporation, Enzon Pharmaceutical Inc., Pacgen Life Science Corporation, Biosergen AS, N8 Medical LLC.

North America was the largest region in the systemic aspergillosis and systemic candidiasis market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the systemic aspergillosis and systemic candidiasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the systemic aspergillosis and systemic candidiasis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of treatments for systemic aspergillosis and systemic candidiasis include systemic oral azoles, voriconazole, liposomal amphotericin B, topical antifungal agents, and others. Systemic oral azoles constitute a class of antifungal medications taken orally to combat systemic fungal infections throughout the body. These drugs target specific enzymes crucial for fungal survival, thereby inhibiting the growth and replication of fungal cells. They find application in treating conditions such as allergic bronchopulmonary aspergillosis (ABPA), chronic pulmonary aspergillosis (CPA), gastrointestinal candidiasis, genitourinary tract candidiasis, and others. The usage is prevalent in clinics, hospitals, and other healthcare settings.

The systemic aspergillosis and systemic candidiasis research report is one of a series of new reports that provides systemic aspergillosis and systemic candidiasis market statistics, including the systemic aspergillosis and systemic candidiasis industry's global market size, regional shares, competitors with systemic aspergillosis and systemic candidiasis market share, detailed systemic aspergillosis and systemic candidiasis market segments, market trends and opportunities, and any further data you may need to thrive in the systemic aspergillosis and systemic candidiasis industry. This systemic aspergillosis and systemic candidiasis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The systemic aspergillosis and systemic candidiasis market consists of sales of voriconazole and amphotericin B. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.